РЕВМАТОИДНЫЙ АРТРИТ: ЛАБОРАТОРНЫЕ МОДЕЛИ ЗАБОЛЕВАНИЯ
Аннотация
Эффективным подходом к исследованию ревматоидного артрита (РА) является создание и использование моделей животных. Экспериментальное изучение различных аспектов формирования и течения РА, включая ранний РА, позволяют приблизиться к пониманию этиопатогенетических механизмов заболевания человека. В обзоре рассматриваются известные в настоящее время модели заболевания. Использование этих моделей для тестирования потенциальных терапевтических препаратов поможет прогнозировать их эффективность
Об авторах
И. А. Орловская
Научно-исследовательский институт фундаментальной и клинической иммунологии, г. Новосибирск
Россия
Россия
Доктор медицинских наук, профессор, заведующая лабораторией иммунобиологии стволовой клетки ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии», г. Новосибирск.
Адрес для переписки: Орловская Ирина Анатольевна ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии» 630099, Россия, г. Новосибирск, ул. Ядринцевская, 14. Тел.: 8 (913) 748-60-99. E-mail:irorl@mail.ru
Д. Д. Цырендоржиев
Научно-исследовательский институт фундаментальной и клинической иммунологии, г. Новосибирск
Россия
Доктор медицинских наук, профессор, ведущий научный сотрудник ФГБНУ «Научноисследовательский институт фундаментальной и клинической иммунологии», г. Новосибирск
Россия
Доктор медицинских наук, профессор, ведущий научный сотрудник ФГБНУ «Научноисследовательский институт фундаментальной и клинической иммунологии», г. Новосибирск
С. Н. Щелкунов
«Вектор», п. Кольцово, Новосибирская область,
Россия
Доктор биологических наук, профессор, заведующий отделом геномных исследований и разработки методов ДНК-диагностики поксвирусов ФГУН ГНЦ ВБ «Вектор» Роспотребнадзора, п. Кольцово, Новосибирская область
Россия
Доктор биологических наук, профессор, заведующий отделом геномных исследований и разработки методов ДНК-диагностики поксвирусов ФГУН ГНЦ ВБ «Вектор» Роспотребнадзора, п. Кольцово, Новосибирская область
Список литературы
1. Adarichev V.A., Vermes C., Hanyecz A., Mikecz K., Bremer E.G., Glant T.T. Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation. Arthritis Res. Ther., 2005, Vol. 7, рр. 196-207.
2. Bendele A.M. Animal models of rheumatoid arthritis. J. Musculoskel. Neuron Interact., 2001, Vol. 1, pp. 377-385.
3. Benito M.J., Sanchez-Pernaute O., Lopez-Armada M.J., Hernandez P. et al Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. Arthritis Rheum., 2000, Vol. 43, pp. 311-319.
4. Berlo S.E., Guichelaar T., Ten Brink C.B., van Kooten P.J., Hauet-Broeren F., Ludanyi K., et al. Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis Rheum., 2006, Vol. 54, pp. 2423-2433.
5. Brand D.D. Rodent models of rheumatoid arthritis. Comp. Med., 2005, Vol. 55, pp. 114-122.
6. Brand D.D., Kang A.H., Rosloniec E.F. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol., 2003, Vol. 25, pp.3-18.
7. Bush K.A., Walker J.S., Lee C.S., Kirkham B.W. Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease. Clin. Exp. Immunol., 2001, Vol. 123, pp. 487-495.
8. Cannon G.W., McCall S., Cole B.C., Griffiths M.M., Radov L.A., Ward J.R. Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice. Agents Actions, 1990, Vol. 29, pp. 315-323.
9. Carlsén S., Hansson A.S., Olsson H., Heinegård D., Holmdahl R. Cartilage oligomeric matrix protein (COMP)induced arthritis in rats. Clin. Exp. Immunol., 1998, Vol. 114.
10. Carlson R.P., Datko L.J., O’Neill-Davis L., Blazek E.M., deLustro F., Beideman R. Comparison of inflammatory changes in established type II collagenand adjuvant-induced arthritis using outbred Wistar rats. Int. J. Immunopharmacol., 1985, Vol. 7, pp. 811-826.
11. Chen M., Lam B.K., Kanoaka Y., Nigrovic P.A., Audoly L.P., Austen K.F., Lee D.M. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med., 2006, Vol. 203, pp. 837-842.
12. DeJoy S.Q., Reguson K.M., Sapp T.M., Zabriskie J.B., Oronsky A.L., Kerwar S.S. Streptococcal cell wall arthritis. Passive transfer of disease with a T cell line and crossreactivity of streptococcal cell wall antigens with mycobacterium tuberculosis. J. Exp. Med., 1989, Vol. 170, pp. 369-382.
13. Dittel B.N., Visintin I., Merchant R.M., Janeway, C.A. Presentation of the self-antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol., 1999, Vol. 163, pp. 32-36. 14. Edwards J.C.W., Sedgwick A.D., Willoughby D.A. The formation of a structure with features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J. Pathology, 1981, Vol. 134, pp. 147-156.
14. Goodson T., Morgan S.L., Carlee J.R., Baggott J.E. The energy cost of adjuvant-induced arthritis in rats. Arthritis Rheum., 2003, Vol. 48, pp. 2979-2982.
15. Holmdahl R., Andersson M.E., Goldschmidt T.J., Jansson L., Karlsson M., Malmstrom V. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS, 1989, Vol. 97, pp. 575-584.
16. Holmdahl R., Bockermann R., Backlund J., Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice – a model for rheumatoid arthritis. Ageing Res. Rev., 2002, Vol. 1, pp. 135-147.
17. Huh J.E., Hong J.M., Baek Y.H., Lee J.D., Choi D.Y., Park D.S. Anti-inflammatory and anti-nociceptive effect of Betula platyphylla var. japonica in human interleukin-1β-stimulated fibroblast-like synoviocytes and in experimental animal models. J. Ethnopharmacol., 2011, Vol. 135, pp. 126-134.
18. Jansson A.M., Lorentzen J.C., Bucht A. CD8+ cells suppress oil-induced arthritis. Clin. Exp. Immunol., 2000, Vol. 120, pp. 532-536.
19. Joe B., Griffiths M.M., Remmers E.F., Wilder R.L. Animal models of rheumatoid arthritis and related inflammation. Curr. Rheumatol. Rep., 1999, Vol. 1, pp. 139-148.
20. Kannan K., Ortmann R.A., Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology, 2005, Vol. 12, pp. 167-181.
21. Kato A., Matsuo S., Takai H., Uchiyama Y., Mihara M., Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp. Mol. Pathol., 2008, Vol. 84, pp. 262-270.
22. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J., 1991, Vol. 10, pp. 40254031.
23. Kimpel D., Dayton T., Hannan K., Wolf R.E. Streptococcal cell-wall arthritis: kinetics of immune cell activation in inflammatory arthritis. Clin. Immunol., 2002, Vol. 105, pp. 351-362.
24. Koga T., Kakimoto K., Hirofuji T., Kotani S., Ohkuni H., Watanabe K. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect. Immun., 1985, Vol. 50, pp. 27-34.
25. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell, 1996, Vol. 87, pp. 811-822.
26. Kyburz D., Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin. Immunopathol., 2003, Vol. 25, pp. 79-90.
27. Leung B.P., Conacher M., Hunter D., McInnes I.B., Liew F.Y., Brewer J.M. A Novel Dendritic Cell-Induced Model of Erosive Inflammatory Arthritis: Distinct Roles for Dendritic Cells in T Cell Activation and Induction of Local Inflammation. J. Immunol., 2002, Vol. 169, pp. 7071-7077.
28. Linton S.M., Morgan B.P. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol., 1999, Vol. 36, pp. 905-914.
29. Ma Y., Seiler K.P., Eichwald E.J., Weis J.H., Teuscher C., Weis J.J. Distinct characteristics of resistance to Borrelia burgdorferi-induced arthritis in C57BL/6N mice. Infect. Immun., 1998, Vol. 66, pp. 161-168.
30. Maccioni M., Zeder-Lutz G., Huang H., Ebel C., Gerber P., Hergueux J. et al. Arthritogenic monoclonal antibodies from K/BxN mice. J. Exp. Med., 2002, Vol. 195, pp. 1071-1077.
31. Makarov S.S., Olsen J.C., Johnston W.N., Anderle S.K., Brown R.R., Baldwin Jr. A.S., Haskill J.S., Schwab J.H. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc. Natl. Acad. Sci. USA, 1996, Vol. 93, pp. 402-406.
32. Martinez-Lostao L., Garcia-Alvarez F., Basanez G., Alegre-Aguaron E. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum., 2010, Vol. 62, pp. 2272-2282.
33. Matsumoto M., Maccioni M., Lee D.M., Maurice M., Simmons B., Brenner M. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat. Immunol., 2002, Vol. 3, pp. 360-365.
34. Mihara M., Kotoh M., Nishimoto N., Oda Y., Kumagai E., Takagi N., Tsunemi K., Ohsugi Y., Kishimoto T., Yoshizaki K., Takeda Y. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol., 2001, Vol. 98, pp. 319-326.
35. Mortiz F., Distler O., Ospelt C., Gay R.E., Gay S. Technology insight: gene transfer and the design of novel treatment for rheumatoid arthritis. Nat. Clin. Pract. Rheum., 2006, Vol. 2, pp. 153-162.
36. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent proand anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med., 2003, Vol. 198, pp. 1951-1957.
37. Myers L.K., Seyer J.M., Stuart J.M., Terato K., David C.S., Kang A.H. T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J. Immunol., 1993, Vol. 151, pp. 500-505.
38. Okura T., Marutsuka K., Hamada H., Sekimoto T. Therapeutic efficacy of intra-articular adrenomedullin injection in antigen-induced arthritis in rabbits. Arthritis Res. Ther., 2008, Vol. 10, pp. 133-138.
39. Pearson C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc. Soc. Exp. Biol. Med., 1956, Vol. 91, pp. 95-101.
40. Рerruche S., Saas P., Chen W. Apoptotic cell-mediated suppression of streptococcal cell wall-induced arthritis is associated with alteration of macrophage function and local regulatory T-cell increase: a potential cell-based therapy? Arthritis Res. Ther., 2009, Vol. 11, pp. 104-110.
41. Res P.C., Schaar C.G., Breedveld F.C., van Eden W., vanEmbden J.D., Cohen I.R., de Vries R.R. Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet, 1988, Vol. 2, pp. 478-480.
42. Rioja C.L. Clayton S.J. Graham P.F. Life M.C. Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis. Arthritis Res. Ther., 2005, Vol. 7, pp.101-117.
43. Sakiniene E., Collins L.V. Combined antibiotic and free radical trap treatment is effective at combating Staphylococcus aureus-induced septic arthritis. Arthritis Res., 2002, Vol. 4, pp. 196-200. 210 Orlovskaya I.A. et al. Орловская И.А. и др. Medical Immunology (Russia)
44. Schubert D., Maier B., Morawietz L., Krenn V., Kamradt T. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J. Immunol., 2004, Vol. 172, pp. 45034509.
45. Schwab J.H., Brown R.R., Anderle S.K., Schlievert P.M. Superantigen can reactivate bacterial cell wall-induced arthritis. J. Immunol., 1993, Vol. 150, pp. 4151-4159.
46. Sedgwick A.D., Sin Y.M., Edwards J.C.W., Willoughby D.A. Increased inflammatory activity of newly formed lining tissue. J. Pathol., 1983, Vol. 141, pp. 483-495.
47. Selye H. On the mechanism through with hydrocortisone affects the resistance of tissues to injury. An experimental study with granuloma pouch technique. JAMA, 1953, Vol. 152, pp.1207-1213.
48. Steinman, R. M. DC-SIGN: a guide to some mysteries of dendritic cells. Cell, 2000, Vol. 100, pp. 491-494.
49. Stuart J.M., Townes A.S., Kang A.H. Collagen autoimmune arthritis. Annu. Rev. Immunol., 1984, Vol. 2, pp. 199-218.
50. Taneja V., Behrens M., Mangalam A., Griffiths M.M., Luthra H.S., David C.S. New humanized HLA-DR4transgenic mice that mimic the sex bias of rheumatoid arthritis. Arthritis Rheum., 2007, Vol. 56, pp. 69-78.
51. Terato K., Harper D.S., Griffiths M.M., Hasty D.L., Ye X.J., Cremer M.A. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity, 1995, Vol. 22, pp. 137-147.
52. Trentham D.E. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis Rheum., 1982, Vol. 25, pp. 911-916.
53. Van Lent P., Nabbe K.C., Boross P., Blom A.B., Roth J., Holthuysen A., Sloetjes A., Verbeek S., van den Berg W. The inhibitory receptor FcgammaRII reduces joint inflammation and destruction in experimental immune complexmediated arthritides not only by inhibition of FcgammaRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol., 2003, Vol. 163, pp. 1839-1848.
54. Vingsbo C., Jonsson R., Holmdahl R. Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes. Clin. Exp. Immunol., 1995, Vol. 99, pp. 359-363.
55. Vital E.M., Emery P. The development of targeted therapies in rheumatoid arthritis. J. Autoimmun., 2008, Vol. 31, pp. 219-227.
56. Waksman B.H. Immune regulation in adjuvant disease and other arthritis models:relevance to pathogenesis of chronic arthritis. Scand. J. Immunol., 2002, Vol. 56, pp. 12-34.
57. Watson W.C., Brown P.S., Pitcock J.A., Townes A.S. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57Bl/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum., 1987, Vol. 30, pp. 460-465.
58. Willliams R.O. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol. Med., 2004, Vol. 98, pp. 207-216.
59. Williams R.O. Collagen-induced arthritis in mice: major role for tumor necrosis factor α. Methods Mol. Biol., 2007, Vol. 361, pp. 265-284.
60. Williams R.O., Malfait A.M., Butler D.M., Walmsley M.J., Feldmann M., Maini R.N. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin. Exp. Rheum., 1999, Vol. 17, pp. 115-120.
61. Wooley P.H., Dutcher J., Widmer M.B., Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol., 1993, Vol. 151, pp. 66026607.
62. Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L., Senices M., Wu P.W., Sibley B., Leathurby Y., Brown T.P., Nickerson-Nutter C., Keith J.C. Jr., Collins M. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum., 2007, Vol. 56, pp. 1152-1163.
63. Zhu W., Meng L., Jiang C., Hou W., Xu J., Wang B., Lu S. Induction of toll-like receptor 2 positive antigenpresenting cells in spleen of pristane-induced arthritis in rats. Mol. Biol. Rep., 2012, Vol. 39, pp. 3667-3673
При поддержке: Российский научный фонд
Для цитирования:
Орловская И.А., Цырендоржиев Д.Д., Щелкунов С.Н. РЕВМАТОИДНЫЙ АРТРИТ: ЛАБОРАТОРНЫЕ МОДЕЛИ ЗАБОЛЕВАНИЯ. Медицинская иммунология. 2015;17(3):203-210. https://doi.org/10.15789/1563-0625-2015-3-203-210
For citation:
Orlovskaya I.A., Tsyrendorzhiev D.D., Shchelkunov S.N. RHEUMATOID ARTHRITIS: LABORATORY MODELS OF THE DISEASE. Medical Immunology (Russia). 2015;17(3):203-210. (In Russ.) https://doi.org/10.15789/1563-0625-2015-3-203-210
Просмотров: 1194
Послать статью по эл. почте 